Prothena reported $371.44M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
ALKERMES USD 521.2M 121.39M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Exelixis USD 164.43M 19.32M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
MacroGenics USD 130.69M 52.15M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Prothena USD 371.44M 99.95M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025